Evidence map›Paper›PMID 28097472›Full record

ReviewCancer causes & control : CCC2017

Proceedings of the third international molecular pathological epidemiology (MPE) meeting.

Peter T Campbell, Timothy R Rebbeck, Reiko Nishihara, Andrew H Beck, Colin B Begg, Alexei A Bogdanov, Yin Cao, Helen G Coleman, Gordon J Freeman, Yujing J Heng and 21 more

Open access · greenAbstract readReview
In one paragraph

Review in Cancer causes & control : CCC, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Energy sensing pathways: Bridging type 2 diabetes and colorectal cancer?Journal of diabetes and its complications · 2017
    Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 12 institutions in 2 countries.

Peter T CampbellEpidemiology Research Program, American Cancer Society, 250 Williams Street NW, Atlanta, GA, 30303, USA. peter.campbell@cancer.org.
Timothy R RebbeckDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Reiko NishiharaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Andrew H BeckCancer Research Institute, Beth Israel Deaconess Cancer Center, Boston, MA, USA.
Colin B BeggDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alexei A BogdanovDepartment of Radiology, University of Massachusetts Medical School, Worcester, MA, USA.
Yin CaoDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Helen G ColemanEpidemiology and Health Services Research Group, Centre for Public Health, Queens University Belfast, Belfast, Northern Ireland.
Gordon J FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Yujing J HengCancer Research Institute, Beth Israel Deaconess Cancer Center, Boston, MA, USA.
Curtis HuttenhowerDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Rafael A IrizarryDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
N Sertac KipLaboratory Medicine and Pathology, Geisinger Health System, Danville, PA, USA.
Franziska MichorDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Daniel NevoDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Ulrike PetersPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Amanda I PhippsPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Elizabeth M PooleDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Zhi Rong QianDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
John QuackenbushDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Harlan RobinsPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Peter K RoganDepartment of Biochemistry, University of Western Ontario, London, Canada.
Martha L SlatteryUniversity of Utah School of Medicine, Salt Lake City, UT, USA.
Stephanie A Smith-WarnerDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Mingyang SongDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Tyler J VanderWeeleDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Daniel XiaDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Emily C ZaborDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Xuehong ZhangChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Molin WangDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Shuji OginoDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Shuji_ogino@dfci.harvard.edu.
Harvard University · USBrigham and Women's Hospital · USMemorial Sloan Kettering Cancer Center · USSeattle University · USAmerican Cancer Society · USDana-Farber Cancer Institute · USFred Hutch Cancer Center · USGeisinger Health System · USMassachusetts General Hospital · USUniversity of Massachusetts Chan Medical School · USUniversity of Utah · USWestern University · CA

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI Irene M. Ghobrial · 1985 to 2026
$330.6M
Project 3: Single Cell Measures of Intratumor Diversity for Optimal Breast Cancer TherapyU54CA193461 · NCI · DANA-FARBER CANCER INST · PI SCADDEN, DAVID T · 2015 to 2020
$11.2M
miRNA and colorectal cancer: associations with tumor phenotype and survivalR01CA163683 · NCI · UNIVERSITY OF UTAH · PI SLATTERY, MARTHA L · 2012 to 2017
$6.5M
Accelerating Transdisciplinary Epidemiology of Colorectal CancerR35CA197735 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2015 to 2021
$6.0M
Lifestyle Factors and Survival Outcomes for Colorectal Cancer Molecular SubtypesK07CA172298 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PHIPPS, AMANDA IRENE · 2013 to 2016
$406k
The Third International Molecular Pathological Epidemiology (MPE) MeetingR13CA203287 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2016 to 2016
$20k
Cancer Research UK 15333Cancer Research UK 17592NCI NIH HHS K07 CA172298NCI NIH HHS P30 CA006516NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA163683NCI NIH HHS R13 CA203287NCI NIH HHS R35 CA197735NCI NIH HHS U54 CA193461
6 · The paper itself

Abstract

Molecular pathological epidemiology (MPE) is a transdisciplinary and relatively new scientific discipline that integrates theory, methods, and resources from epidemiology, pathology, biostatistics, bioinformatics, and computational biology. The underlying objective of MPE research is to better understand the etiology and progression of complex and heterogeneous human diseases with the goal of informing prevention and treatment efforts in population health and clinical medicine. Although MPE research has been commonly applied to investigating breast, lung, and colorectal cancers, its methodology can be used to study most diseases. Recent successes in MPE studies include: (1) the development of new statistical methods to address etiologic heterogeneity; (2) the enhancement of causal inference; (3) the identification of previously unknown exposure-subtype disease associations; and (4) better understanding of the role of lifestyle/behavioral factors on modifying prognosis according to disease subtype. Central challenges to MPE include the relative lack of transdisciplinary experts, educational programs, and forums to discuss issues related to the advancement of the field. To address these challenges, highlight recent successes in the field, and identify new opportunities, a series of MPE meetings have been held at the Dana-Farber Cancer Institute in Boston, MA. Herein, we share the proceedings of the Third International MPE Meeting, held in May 2016 and attended by 150 scientists from 17 countries. Special topics included integration of MPE with immunology and health disparity research. This meeting series will continue to provide an impetus to foster further transdisciplinary integration of divergent scientific fields.

Indexed as

EpidemiologyNeoplasmsPathology, MolecularBostonHumansMeeting reportMolecular pathological epidemiologyProceedings

Identifiers

PMID28097472
PMCPMC5303153
OpenAlexW4214817917

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.